GOG to conduct Phase II trial on primary peritoneal cancer
Links shared publicly online about this topic.
- 901total visits
GOG to conduct Phase II trial on primary peritoneal cancer
View full resource at news-medical.net
Tags: Cancer, Cancer Medication, Biotech, Women's Health, Taxol, Oncology
Most Recently Shared on September 3, 2010 at 12:13 pm By:
Oncology News: GOG to conduct Phase II trial on primary peritoneal cancer: Oncolytics Biotech Inc. announced today... http://bit.ly/9nWzJ7
Also Shared By:
Oncolytics initiates enrollment in Phase II ovarian cancer study
news-medical.net — “Oncolytics Biotech Inc. announced today the start of enrollment in a randomized Phase II ovarian cancer study. The Gynecologic Oncology Group (GOG) is conducting the randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H).” View full resource at news-medical.net
Most Recently Shared on December 2, 2010 at 8:52 am By:
Oncolytics initiates enrollment in Phase II ovarian cancer study: Oncolytics Biotech Inc. announced today the st... http://bit.ly/gif7vu
Novel Study Using Reoviruses Against Ovarian Cancer Pushes Forward
newswise.com — “Calgary-based Oncolytics Biotech Inc. recently announced that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer.” View full resource at newswise.com
Most Recently Shared on September 14, 2010 at 4:30 pm By:
newswise Health Communicator and Health News
Novel Study Using Reoviruses Against Ovarian Cancer Pushes Forward: http://bit.ly/aytD49
Novel Study Using Reoviruses Against Ovarian Cancer Pushes Forward
newswise.com — “Calgary-based Oncolytics Biotech Inc. recently announced that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer.” View full resource at newswise.com
Most Recently Shared on September 13, 2010 at 1:25 pm By:
Novel Study Using Reoviruses Against Ovarian Cancer Pushes Forward: Calgary-based Oncolytics Biotech Inc. recently... http://bit.ly/d4wdql
Novel Study Using Reoviruses Against Ovarian Cancer Pushes Forward
newswise.com — “Calgary-based Oncolytics Biotech Inc. recently announced that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer.” View full resource at newswise.com
Most Recently Shared on September 13, 2010 at 9:37 am By:
newswise Health Communicator and Health News
Novel Study Using Reoviruses Against Ovarian Cancer Pushes Forward: Calgary-based Oncolytics Biotech Inc. recently... http://bit.ly/aUNZFT
Advertisement
News-Medical.Net
@NewsMedical
GOG to conduct Phase II trial on primary peritoneal cancer: Oncolytics Biotech Inc. announced today that the Gynec... http://bit.ly/9nWzJ7
1 year ago...